Full Press Release Details
Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021.
VKTX
Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Key Takeaway: Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Price reaction · baseline $5.76 (2021-10-22 close) · 1 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss